n.a. (SHP)

0.00
NYSE
Prev Close 0.00
Day Low/High 0.00 / 0.00
52 Wk Low/High 0.00 / 0.00
Exchange NYSE
Div & Yield N.A. (N.A)

Latest News

Shire's Angioedema Success Could Be a Cure for a Bad Record in M&A

Shire's Angioedema Success Could Be a Cure for a Bad Record in M&A

Shire's success in phase 3 trials of Lanadelumab may mean it has also found a cure for a damaged track record in M&A.

Shire Continues 20-Year Commitment To ADHD With New Research At 2017 Annual Meeting Of American Psychiatric Association

Latest Research Supports Greater Understanding of the Evolving Needs of Adults with ADHD

Earnings and Economics Push European Benchmarks Higher

Earnings and Economics Push European Benchmarks Higher

Markets shrugged off weak industrial data from China to focus on economics and earnings news closer to home

Shire Stock Lifted By First-Quarter Earnings Beat

Shire Stock Lifted By First-Quarter Earnings Beat

Shire plc SHP shares shot to the top of the FTSE 100 Tuesday after the drugmaker beat expectations for earnings in the first-quarter and reiterated its full-year guidance.

Shire Granted EU Conditional Marketing Authorisation For Natpar[®¿] (Parathyroid Hormone) For The Treatment Of Patients With Chronic Hypoparathyroidism

Natpar is the first and only licensed recombinant human parathyroid hormone therapy for chronic hypoparathyroidism

Shire Launches #PIPostsThanks Social Campaign To Raise Awareness Of Primary Immunodeficiency (PI)

Shire launches campaign to raise global awareness during World PI Week

PatientsLikeMe And Shire Pharmaceuticals Collaborate To Study Rare Genetic Diseases

PatientsLikeMe and Shire plc (LSE: SHP, NASDAQ: SHPG) have announced a new collaboration that will support the development of a patient-centered, real world health learning system that expands understanding of...

Risky Stocks Rise in Europe but Banks Lag

Risky Stocks Rise in Europe but Banks Lag

Benchmarks were higher on Tuesday following strong gains among commodity, consumer and airline stocks

CUVITRU [Immune Globulin Subcutaneous (Human), 20% Solution] Data Demonstrate Improved Treatment Satisfaction Relative To Patients' Previous Immunoglobulin Therapy

Shire data presentations at AAAAI 2017 reinforce the efficacy, safety, and tolerability of CUVITRU for primary immunodeficiency patients

New Data From Shire Aim To Help Close The Diagnosis And Treatment Gap For People With Hemophilia

Shire presentations at EAHAD 2017 underscore the company's leadership in improving global standards of care